- Trials with a EudraCT protocol (64)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
64 result(s) found for: Component causes.
Displaying page 1 of 4.
EudraCT Number: 2005-002389-13 | Sponsor Protocol Number: | Start Date*: 2005-11-23 |
Sponsor Name:Moorfields Eye Hospital | ||
Full Title: Endothelial Lamellar Keratoplasty (ELK) with Tisseel adhesive. | ||
Medical condition: Corneal endothelial failure, from Fuchs' corneal endothelial dystrophy, aphakic and pseudophakic bullous keratopathy and other causes. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002584-27 | Sponsor Protocol Number: AC-054-301 | Start Date*: 2007-11-07 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus... | |||||||||||||
Medical condition: Indication: Aneurysmal subarachnoid hemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) FI (Completed) SE (Completed) DE (Completed) AT (Completed) DK (Completed) ES (Completed) CZ (Completed) IT (Completed) SI (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006785-29 | Sponsor Protocol Number: AC-054-302 | Start Date*: 2009-09-15 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus... | |||||||||||||
Medical condition: Indication: Subarachnoid aneurysmal hemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) DE (Completed) SI (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004505-16 | Sponsor Protocol Number: CONVINCE | Start Date*: 2016-08-08 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:University College Dublin | ||||||||||||||||||||||||||||||||||||||
Full Title: CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic stroke) – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke | ||||||||||||||||||||||||||||||||||||||
Medical condition: The prevention of recurrent stroke and coronary events (fatal and non- fatal) after ischaemic stroke and transient ischaemic attack (TIA) not caused by cardiac embolism or other causes unrelated to... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: IE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) DK (Completed) PT (Completed) BE (Completed) LT (Completed) NL (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004318-14 | Sponsor Protocol Number: NEOD001-201 | Start Date*: 2016-06-13 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction | |||||||||||||
Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Completed) GR (Completed) ES (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001462-33 | Sponsor Protocol Number: 26866138-MMY-2045 | Start Date*: 2008-01-03 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of VELCADE® in combination with Dexamethasone or VELCADE® in combination with Dexamethasone ... | |||||||||||||
Medical condition: multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) LT (Completed) HU (Completed) ES (Completed) GR (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023799-21 | Sponsor Protocol Number: H9X-MC-GBDJ | Start Date*: 2011-10-06 | |||||||||||
Sponsor Name:Eli Lilly & Company | |||||||||||||
Full Title: The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) | |||||||||||||
Medical condition: Cardiovascular events in patients with Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed) GB (Completed) PL (Completed) ES (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004585-25 | Sponsor Protocol Number: I1F-MC-RHCF | Start Date*: 2017-05-26 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A 52-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-... | |||||||||||||
Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) AT (Completed) SE (Completed) DK (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002735-28 | Sponsor Protocol Number: I8F-MC-GPGN | Start Date*: 2020-03-30 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT) | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DE (Ongoing) SK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004664-18 | Sponsor Protocol Number: NEOD001-OLE251 | Start Date*: 2017-08-08 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO) | |||||||||||||
Medical condition: The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who completed Study NEOD001 201 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006176-30 | Sponsor Protocol Number: NW-1029/01-08 | Start Date*: 2009-03-13 | |||||||||||
Sponsor Name:Newron Pharmaceuticals S.p.A. | |||||||||||||
Full Title: EFFICACY AND SAFETY OF TWO FIXED DOSES (160 OR 320 MG/DAY) OF RALFINAMIDE IN PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN. A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED 12- WEEK ST... | |||||||||||||
Medical condition: Chronic neuropathic low back pain. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000658-27 | Sponsor Protocol Number: D5130C05262 | Start Date*: 2006-12-12 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute C... | |||||||||||||
Medical condition: non-ST and ST elevation acute coronary syndromes (ACS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) PT (Completed) HU (Completed) DE (Completed) FR (Completed) SE (Completed) AT (Completed) NL (Completed) DK (Completed) SK (Completed) BE (Completed) CZ (Completed) GR (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000037-14 | Sponsor Protocol Number: NEOD001-301 | Start Date*: 2021-09-01 | |||||||||||
Sponsor Name:Prothena Biosciences Limited | |||||||||||||
Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with ... | |||||||||||||
Medical condition: AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) GR (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001954-40 | Sponsor Protocol Number: SPh/01/2014 | Start Date*: 2014-10-02 | |||||||||||
Sponsor Name:SciencePharma spółka z ograniczoną odpowiedzialnością sp. k. | |||||||||||||
Full Title: A randomized, multicenter, parallel, open-label study comparing the safety of the test investigational medicinal product (IMP) Enoxaparin Sodium 40 with the reference IMP Clexane for the prevention... | |||||||||||||
Medical condition: Prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk knee surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001910-13 | Sponsor Protocol Number: AV-101-002 | Start Date*: 2022-02-21 | ||||||||||||||||||||||||||
Sponsor Name:Aerovate Therapeutics, Inc. | ||||||||||||||||||||||||||||
Full Title: IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hy... | ||||||||||||||||||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003865-11 | Sponsor Protocol Number: NEOD001-CL002 | Start Date*: 2015-11-27 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai... | |||||||||||||
Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001343-55 | Sponsor Protocol Number: A6061030 | Start Date*: 2006-08-02 | |||||||||||
Sponsor Name:Pfizer, S.A. | |||||||||||||
Full Title: A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN). | |||||||||||||
Medical condition: Postherpetic neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Prematurely Ended) GB (Completed) LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022293-14 | Sponsor Protocol Number: ANRS146OPTIMAL | Start Date*: 2012-08-22 |
Sponsor Name:Inserm-ANRS | ||
Full Title: Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defi... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002432-93 | Sponsor Protocol Number: NN8828-4004 | Start Date*: 2013-01-18 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of NNC0114-0006 in subjects with active Crohn’s disease | |||||||||||||
Medical condition: Crohns disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001750-42 | Sponsor Protocol Number: CA209-214 | Start Date*: 2014-11-11 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma | |||||||||||||||||||||||
Medical condition: Advanced or metastatic renal cell carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Trial now transitioned) NL (Trial now transitioned) IE (Trial now transitioned) PL (Completed) FR (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
